The Notch Signaling Pathway Contributes to Angiogenesis and Tumor Immunity in Breast Cancer
Nina Jiang,Ye Hu,Meiling Wang,Zuowei Zhao,Man Li
DOI: https://doi.org/10.2147/BCTT.S376873
2022-09-27
Breast Cancer: Targets and Therapy
Abstract:Nina Jiang, 1, &ast Ye Hu, 1, &ast Meiling Wang, 2, &ast Zuowei Zhao, 2 Man Li 1 1 Department of Oncology, the Second Hospital of Dalian Medical University, Dalian, Liaoning, People's Republic of China; 2 Department of Breast Surgery, the Second Hospital of Dalian Medical University, Dalian, Liaoning, People's Republic of China &astThese authors contributed equally to this work Correspondence: Zuowei Zhao, Department of Breast Surgery, the Second Hospital of Dalian Medical University, Dalian, Liaoning, People's Republic of China, Tel +86-0411-84671291, Fax +86-0411-84671230, Email Man Li, Department of Oncology, the Second Hospital of Dalian Medical University, Dalian, Liaoning, People's Republic of China, Tel +86-0411-84671291, Fax +86-0411-84671230, Email Breast cancer in women is the first leading tumor in terms of incidence worldwide. Some subtypes of BC lack distinct molecular targets and exhibit therapeutic resistance; these patients have a poor prognosis. Thus, the search for new molecular targets is an ongoing challenge for BC therapy. The Notch signaling pathway is found in both vertebrates and invertebrates, and it is a highly conserved in the evolution of the species, controlling cellular fates such as death, proliferation, and differentiation. Numerous studies have shown that improper activation of Notch signaling may lead to excessive cell proliferation and cancer, with tumor-promoting and tumor-suppressive effects in various carcinomas. Thus, inhibitors of Notch signaling are actively being investigated for the treatment of various tumors. The role of Notch signaling in BC has been widely studied in recent years. There is a growing body of evidence suggesting that Notch signaling has a pro-oncogenic role in BC, and the tumor-promoting effect is largely a result of the diverse nature of tumor immunity. Immunological abnormality is also a factor involved in the pathogenesis of BC, suggesting that Notch signaling could be a target for BC immunotherapies. Furthermore, angiogenesis is essential for BC growth and metastasis, and the Notch signaling pathway has been implicated in angiogenesis, so studying the role of Notch signaling in BC angiogenesis will provide new prospects for the treatment of BC. We summarize the potential roles of the current Notch signaling pathway and its inhibitors in BC angiogenesis and the immune response in this review and describe the pharmacological targets of Notch signaling in BC, which may serve as a theoretical foundation for future research into exploring this pathway for novel BC therapies. Keywords: Notch signaling pathway, angiogenesis, tumor immunity, breast cancer, PD-1/PD-L1 Breast cancer (BC) is the most common malignant tumor in women. As of 2020, global tumor data indicated that BC incidence surpassed that of lung cancer and has developed into the major malignant tumor in women around the world. 1 Clinically, different subtypes of BC lack specific molecular targets and exhibit drug resistance, and treatment is less effective. Therefore, the search for a new specific target molecule for BC therapy is a current therapeutic challenge. The previous studies demonstrated that BC is the first solid tumor in which associated with Notch was identified, and there is also an emerging opinion that Notch signaling is one of the three main culprits of breast cancer. 2,3 Studies have found increased expression of members of the Notch family in BC tissues, compared to normal control tissues. Triple-negative BC (TNBC) exhibits abnormally activated Notch signaling. The overexpression of the Notch receptor is highly correlated with the invasiveness, metastasis, and drug resistance of TNBC. 4,5 And several studies have indicated a crucial association between BC and members of the Notch family [Table 1]. Table 1 Relationship Between Notch Receptors and Different Types of Breast Cancer Notch1 overexpression is associated with a poor prognosis and BC progression and the transition from ductal carcinoma in situ to invasive BC. 6,7 Mutations in Notch2 can increase the incidence of BC, and the mutation rate is positively correlated with the progression of HER2-positive BC. Furthermore, the susceptibility to BC has been strongly associated with the Notch2 variant rs11249433. 8–10 Notch3 overexpression is related to BC invasion and distant metastasis and is also related to the advancement of HER2-negative BC. 11,12 TNBC has been reported to exhibit Notch4 expression in 55.6% of cases, while HER2-positive cases occur in 45.8% and in 25.5% of luminal cases. 13,14 Highly metastatic BC cells can exhibit higher P2Y 2 receptors (P2Y 2 R), and P2Y 2 -Abstract Truncated-